002737.SHE Sunflower Pharmaceuticals Group Co Ltd
- Market cap
- CNY 6.98B
- P/E
- -
- P/B
- 1.82x
- ROE
- 2.9%
- Dividend yield
- 4.18%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002737.SHE undervalued?
Graham numberThe Graham number of Sunflower Pharmaceuticals Group Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sunflower Pharmaceuticals Group Co Ltd fundamental analysis
No fundamental analysis for Sunflower Pharmaceuticals Group Co Ltd yet.
Sunflower Pharmaceuticals Group Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sunflower Pharmaceuticals Group Co Ltd
Sunflower Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of Chinese medicines in China and internationally. It offers traditional Chinese medicines, chemical drugs, biological drugs, and health and wellness products, as well as adult and children's medicines for various therapeutic areas, including pediatrics, gynecology, digestive system, respiratory and cold ailments, rheumatism and bone disease, c…
Full company profileSunflower Pharmaceuticals Group Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sunflower Pharmaceuticals Group Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 3.36B | 3.86B | 4.47B | 4.37B | 3.46B | 4.46B | 5.09B | 5.70B | 3.38B | 2.32B | 2.82B |
| Gross Profit | 1.95B | 2.29B | 2.63B | 2.54B | 2.01B | 2.64B | 2.94B | 3.21B | 1.48B | 884M | 1.55B |
| Operating Income | 343M | 555M | 716M | 760M | 767M | 885M | 1.08B | 1.37B | 636M | -212M | 159M |
| EBITDA | 481M | 649M | 780M | 852M | 811M | 936M | 1.29B | 1.36B | 626M | -94.3M | 159M |
| Net Income | 303M | 424M | 563M | 565M | 584M | 705M | 867M | 1.12B | 492M | -258M | 111M |
| EPS | 0.52 | 0.73 | 0.96 | 0.97 | 1.01 | 1.21 | 1.48 | 1.92 | 0.84 | -0.44 | 0.19 |
| Balance Sheet | |||||||||||
| Total Assets | 4.22B | 4.47B | 5.06B | 5.31B | 5.11B | 5.64B | 7.03B | 6.88B | 5.83B | 5.33B | 5.37B |
| Total Liabilities | 1.42B | 1.31B | 1.62B | 1.88B | 1.72B | 1.70B | 2.59B | 1.88B | 1.24B | 1.34B | 1.42B |
| Shareholders' Equity | 2.64B | 2.99B | 3.27B | 3.22B | 3.18B | 3.71B | 4.20B | 4.76B | 4.38B | 3.84B | 3.80B |
| Cash & Short-term Investments | 906M | 932M | 1.23B | 1.67B | 1.80B | 1.99B | 3.85B | 3.60B | 2.30B | 853M | 1.10B |
| Total Debt | 330M | 100M | 196M | 426M | 310M | 244M | 436M | 22.1M | 4.05M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 341M | 559M | 866M | 981M | 1.17B | 865M | 1.97B | 923M | -307M | 575M | - |
| Capital Expenditure | 159M | 157M | 321M | 374M | 213M | 118M | 153M | 149M | 92.8M | 96.1M | 102M |
| Free Cash Flow | 182M | 402M | 545M | 607M | 957M | 747M | 1.82B | 741M | -400M | 479M | 6.34M |
| Ratios | |||||||||||
| ROE | 11.5% | 14.2% | 17.2% | 17.5% | 18.4% | 19.0% | 20.6% | 23.5% | 11.2% | -6.7% | 2.9% |
| ROA | 7.2% | 9.5% | 11.1% | 10.6% | 11.4% | 12.5% | 12.3% | 16.3% | 8.4% | -4.8% | 2.1% |
| Net Profit Margin | 9.0% | 11.0% | 12.6% | 12.9% | 16.9% | 15.8% | 17.0% | 19.6% | 14.6% | -11.1% | 3.9% |
| Debt to Equity | 0.13x | 0.03x | 0.06x | 0.13x | 0.10x | 0.07x | 0.10x | 0.00x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sunflower Pharmaceuticals Group Co Ltd dividends
- Dividend yield
- 4.18%
- Forward dividend
- 0.20 CNY
- Payout ratio
- -
- Ex-dividend date
- Jul 17, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 292M | 0.50 | - |
| 2024 | CNY 885M | 1.51 | 179.9% |
| 2023 | CNY 589M | 1.01 | 52.6% |
| 2022 | CNY 407M | 0.70 | 46.9% |
| 2021 | CNY 202M | 0.35 | 28.6% |
| 2020 | CNY 582M | 1.01 | 99.7% |
| 2019 | CNY 584M | 1.00 | 103.3% |
| 2018 | CNY 300M | 0.51 | 53.2% |
| 2017 | CNY 104M | 0.18 | 24.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Apr 18, 2018.
Who owns Sunflower Pharmaceuticals Group Co Ltd
- Insiders 57.99%
- Institutions 3.47%
- Public & others 38.55%
- Shares outstanding 584M
- Free float 251M
Sunflower Pharmaceuticals Group Co Ltd company profile
- Company name
- Sunflower Pharmaceuticals Group Co Ltd
- Ticker
- 002737.SHE
- ISIN
- CNE100001WT7
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 5,025
- Fiscal year end
- December
- Address
- No. 18, Donghu Road, Harbin, China, 150078
- Phone
- 86 451 8236 7108
- Website
- kuihuayaoye.com
About Sunflower Pharmaceuticals Group Co Ltd
Sunflower Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of Chinese medicines in China and internationally. It offers traditional Chinese medicines, chemical drugs, biological drugs, and health and wellness products, as well as adult and children's medicines for various therapeutic areas, including pediatrics, gynecology, digestive system, respiratory and cold ailments, rheumatism and bone disease, cardiovascular and cerebrovascular diseases, and general health. The company is also involved in leasing and business services; scientific research and technical services; and wholesale and retail trade. It sells its products under the Sunflower and Little Sunflower brand names. The company was founded in 2005 and is headquartered in Harbin, China.
Sunflower Pharmaceuticals Group Co Ltd management
8- Mr. Jianzhong ZhouGM & Non-Independent Director · born 1968
- Ms. Chunhong WuFinancial Manager · born 1977
- Mr. Yang YangDeputy GM & Non-Independent Director · born 1970
- Mr. Guangguang ZhouBoard Secretary · born 1981
- Mr. Guang Tao LiuDeputy General Manager · born 1983
- Mr. Lin XiaoDeputy General Manager · born 1975
- Mr. Peng ZhaoDeputy General Manager · born 1985
- Li ChenAccounting Supervisor